Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Metanephrines (Neuroblastoma)

Clinical study to evaluate the diagnostic significance of metabolites in blood compared to metabolites in urine in children with high-risk neuroblastoma
Who can enter
  • Children with newly diagnosed high-risk neuroblastoma who are being treated according to the SIOPEN HR-NBL-2 protocol
  • Age: 1-18 years


The goal of this study is to investigate the role of specific metabolites that are released in the blood in children with high-risk neuroblastoma.


Neuroblastoma cells can secrete specific metabolites that end up in the urine and blood of neuroblastoma patients. These distinct metabolites can be used to help diagnose neuroblastoma patients. Until now, we always measure the metabolites in urine. Now we want to investigate whether it is more accurate to measure these specific metabolites in blood.

In order to participate in a study please refer to your/your child’s doctor.

Last reviewed

June 28, 2022